Literature DB >> 12809177

Development of Graves' disease in a patient under immunosuppressive therapy after liver transplantation.

T Bednarczuk1, U Makowska, J Nauman.   

Abstract

Susceptibility to Graves' disease (GD) is determined by multiple environmental and genetic factors, which are not fully understood. Because of the autoimmune etiology of the disease, recent reports describing the development of GD during long-term immunosuppressive treatment seem quite surprising. We report a second case of GD in a 17-yr old patient, treated with cyclosporin A and prednisone, after liver transplantation. The development of GD despite adequate immunosuppressive therapy may suggest that this patient had a genetic predisposition to autoimmunity and severe immunoregulatory defects. We analyzed the HLA-DRB1 alleles and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) gene polymorphism (A/G) at position 49 in exon 1. The patient had the HLA-DRB1*03 allele which is known to confer susceptibility to GD. Further studies are necessary to identify genes that may predispose patients specifically to GD during immunosuppressive therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12809177     DOI: 10.1007/BF03345166

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

Review 1.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

Review 2.  The genetics of Graves' disease.

Authors:  S C Gough
Journal:  Endocrinol Metab Clin North Am       Date:  2000-06       Impact factor: 4.741

Review 3.  The HLA system. Second of two parts.

Authors:  J Klein; A Sato
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

Review 4.  Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts.

Authors:  G E Krassas; A E Heufelder
Journal:  Eur J Endocrinol       Date:  2001-04       Impact factor: 6.664

5.  The development of thyrotoxicosis (Graves' disease) during immunosuppression for autoimmune haemolytic anaemia.

Authors:  J A Thomson; R Wilson; I D Walker
Journal:  Acta Endocrinol (Copenh)       Date:  1986-08

6.  Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/tacrolimus.

Authors:  T Lohmann; C List; P Lamesch; K Kohlhaw; M Wenzke; C Schwarz; O Richter; J Hauss; J Seissler
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

7.  CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus.

Authors:  H Donner; H Rau; P G Walfish; J Braun; T Siegmund; R Finke; J Herwig; K H Usadel; K Badenhoop
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

8.  Endocrine ophthalmopathy in a patient under continuous immunosuppressive therapy after cardiac transplantation.

Authors:  G Höfle; R Moncayo; I Baldissera; R Pfister; G Finkenstedt
Journal:  Thyroid       Date:  1995-12       Impact factor: 6.568

9.  Time-dependent effect of cyclosporin-A on the TSH-receptor antibody synthesis in patients with Graves' disease.

Authors:  C Balázs; E Kiss; N R Farid
Journal:  Acta Med Hung       Date:  1988

10.  Thyrotropin receptor epitopes recognized by graves' autoantibodies developing under immunosuppressive therapy.

Authors:  J Wortsman; P McConnachie; K Tahara; L D Kohn
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.